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Fabry (or Anderson Fabry) disease–first described in 1898 by Johannes Fabry in Germany and 
William Anderson in England–is a lysosomal storage disease caused by mutations in 
the GLA gene located on the X chromosome (Xq22.1) [1]. These cause deficiency of the 
enzyme alpha galactosidase A (aGal A) and the accumulation of glycosphingolipids, 
particularly globotriaosylceramide (Gb3), in different cell types. Over 800 individual missense 
or nonsense point mutations, splicing mutations,  deletions and insertions are reported, the 
majority of which render the aGal A enzyme non-functional [2]. Some variants are associated 
with residual aGal A activity (typically 2 to 20% of normal values) that results in attenuated 
forms of the disease. Although Fabry disease (FD) is an X–linked trait, women with GLA 
mutations can develop signs and symptoms of FD which are usually milder than seen in 
affected men but cases of severe disease are well recognised, possibly as the result of skewed 
X chromosome inactivation [3]. 
 
In this edition of the journal, Adalsteinsdottir and colleagues describe the clinical 
phenotypes of two families–identified during genetic screening of Icelandic patients with a 
clinical diagnosis of hypertrophic cardiomyopathy [4]. One family had severe enzyme 
deficiency associated with childhood onset and systemic symptoms and the other had an 
attenuated form characterised by higher residual enzyme activity, later disease onset and 
predominantly cardiac manifestations. As all males over 30 years of age had left ventricular 
hypertrophy, the authors conclude that cardiovascular disease occurs at similar ages, 
despite markedly different α-Gal A activities. 
 
It has become the convention to divide FD into classical and non-classical phenotypes [1]. 
Classical FD is characterised by childhood onset of neuropathic pain, gastrointestinal 
disturbance, cornea verticillata, and cutaneous angiokeratomata. In later decades of life, 
patients with classical disease develop cardiac disease, progressive renal failure, and stroke. 
In contrast, non-classical FD is characterized by a more variable disease course in which 
patients are generally less severely affected with the exception of cardiac disease which is 
often the sole manifestation. Individuals with this non-classical presentation are often 
diagnosed incidentally following genetic or enzymatic screening of patients with ventricular 
hypertrophy. 
 
In general, the findings in the study by Adalsteinsdottir et al are broadly in line with those 
reported in much larger cohort studies.  Left ventricular hypertrophy, arrhythmia, angina and 
dyspnea are reported in approximately 40-60% of patients with FD [5]. Cardiac arrhythmias 
(AV block, atrial fibrillation and ventricular arrhythmia) are common in patients with 
moderate to severe cardiac involvement and may be the cause of premature mortality [6]. As 
patients age, they often develop progressive myocardial fibrosis with a predilection for the 
posterior-lateral left ventricular wall which, in advanced disease, contributes to LV aneurysm 
formation and systolic impairment [7].  
The study by Adalsteinsdottir and colleagues is at variance with the literature in two aspects. 
One is the apparently high incidence of asymmetric patterns of left ventricular hypertrophy 
which are more typically seen in patients with mutations in cardiac sarcomeric protein genes. 
This observation has been reported previously [8], but it is important to consider that the 
asymmetry may result from thinning of the posterior left ventricular wall as a consequence 
of the characteristic pattern of scarring in FD. The practice point is to incorporate all aspects 
of the phenotype when considering differential diagnosis rather than a single parameter such 
as left ventricular wall thickness. 
The second, and more important issue, concerns the natural history of heart disease in 
classical and non-classical disease. This study is too small to address this point, but the 
question has been examined in larger cohort studies. In a recent multicentre study, sex, 
phenotype, and plasma lysoGb3 (the deacylated derivative of Gb3) concentrations were all 
strongly associated with the rate of clinical events and the extent of cardiac, renal, and 
cerebral involvement [9], figure 1. Men with classical FD had an increased risk of developing 
complications and more severe cardiac and renal disease. Women with classical FD had a 
higher risk of developing complications compared with women with non-classical FD. As 
observed in other studies, some women developed cardiac fibrosis in the absence of left 
ventricular hypertrophy for reasons that as yet are unknown.  
When studying patients with a rare disease, factors such as study design, sample size, patient 
characteristics and disease severity must all be considered when drawing general conclusions 
about natural history and by inference treatment goals.  This is particularly true of a 
phenotypically diverse inherited disorder like FD, where it is increasingly recognised that sub-
populations require tailored management and strategies.  
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Figure Legend 
Log–linear regression curve of the LVM measured by echocardiography corrected for height 
(meters2.7). Shaded areas represent the 95% CIs for the fitted curves. The dashed horizontal 
lines represent the upper reference limits (men: 48 g/m2.7; women: 44 g/m2.7).43 Black dots 
represent patients with classical FD, and gray triangles represent patients with nonclassical 
FD. Patients with classical phenotypes have earlier onset and more severe disease. 
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